Endress+Hauser has consolidated its Raman Rxn probe portfolio under a single hyphen-numbered naming scheme that runs from the lab-scale Rxn-10 through the bioprocess Rxn-46, with spec sheets and product pages refreshed through late 2025. The line extends the Kaiser-era platform that the company rebranded in October 2021, and rewires the probe catalogue around application targets rather than legacy model numbers.
What the spec sheets say
The Rxn-30 gas-phase probe uses 532 nm excitation, operates from -20 to 150 C and up to 68.9 barg (1,000 psig), and carries ATEX, CSA, IECEx, UKCA and JPEx hazardous-area approvals. Endress+Hauser positions it for ammonia, methanol, HyCO and hydrogen-liquefaction process gas streams, where ortho/para-hydrogen ratio monitoring drives boil-off losses in the liquid-hydrogen supply chain.
The Rxn-40 immersion probe is offered in 532, 785 and 1000 nm versions, rated -30 to 280 C and up to 182.8 barg (2,651 psig) depending on body diameter and material - C276, 316L stainless or Grade 2 titanium, all with sapphire windows. The Rxn-46 bioprocess probe runs at 785 nm, sits in single-use bioreactors from 15 mL Ambr through 2000 L Biostat STR formats, and ships paired with Sartorius’s BioPAT Spectro controller for cell-culture glucose, lactate, amino-acid, cell-density and titer monitoring.
What it changes for operators
For PAT engineers running vendor comparisons, the renumbered portfolio maps probe selection more directly onto the application: gas-phase to -30, in-situ liquid to -40, bioprocess to -46, with -10 and -20 covering benchtop and headspace cases. The hardware specifications themselves remain consistent with the prior Kaiser-branded line; what moves is documentation hygiene and the explicit Sartorius binding for the bioprocess offer, which keeps the Endress+Hauser stack aligned with the largest single-use bioreactor installed base for buyers weighing Raman against NIR in mammalian cell culture. Procurement teams sourcing inline Raman in 2026 should expect spec-sheet alignment with the criteria Spectrane laid out in the inline Raman buyer’s guide earlier this quarter.